Founded in 2012, Abwiz Bio has over a decade of experience in antibody discovery and engineering. Here, we highlight particular achievements of interest.
Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5
Antibody Therapeutics (2023)
A peer-reviewed study detailing the engineering of broadly neutralizing COVID-19 therapeutic mAbs using our proprietary STEM antibody affinity maturation platform.